Search | IOVS | ARVO Journals

Showing 1 – 20 of 53

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2025

Safety, Tolerability and Efficacy of Intravitreal AM712 for Neovascular Age-Related Macular Degeneration (CONQUER)

Vrinda Hershberger; David Ryan Lally; Eric W Schneider; Charles Clifton Wykoff; Richard G Lane; David M Brown; Roger A Goldberg; Nikolas J London; Jeffrey S Heier; Peter Kaiser; Xiaozhe Zhang; Fiona Ma; Yusong Xia; Wei Wang; Billy Xin; Michelle Zhang; Yutao Ma

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):693.

ARVO Annual Meeting Abstract June 2025

RO-104, a trispecific antibody, significantly reduces vascular leakage and lesion area in laser-induced non-human primate model of CNV

Yixuan Ma; Trevor J McGill; Li Xu; Ashwin Gupta; Manhitha Mamillapalli; Helena Yee; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Mark Barakat; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):4323.

ARVO Annual Meeting Abstract June 2025

RP-060: a potential bispecific molecule targeting both dry AMD and wet AMD pathways

Li Xu; Yixuan Ma; Helena Yee; Peter Kaiser; Arshad M. Khanani; Jeffrey S Heier; Mark Barakat; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):4345.

ARVO Annual Meeting Abstract June 2024

Inhibition of VEGFA induced HUVEC migration via RO-104, a novel trispecific protein

Yixuan Ma; Alina K Sinha; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Parth Patel; Ashwin Gupta; Nikhil Gupta; Megana Paidela; Isabel Ray; Ramesh Bhatt; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1942.

ARVO Annual Meeting Abstract June 2024

Assessment of pre-existing anti-drug antibodies (ADAs) in pooled serum against novel trispecific biologic RO-104 analogs

Isabel Ray; Alina K Sinha; Li Xu; Peter M Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Parth Patel; Nikhil Gupta; Ashwin Gupta; Megana Paidela; Yixuan Ma; Ramesh Bhatt; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):715.

ARVO Annual Meeting Abstract June 2024

Rat Laser CNV Efficacy Studies with the Novel Trispecific Protein RO-104

Alina K Sinha; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Parth Patel; Nikhil Gupta; Ashwin Gupta; Megana Paidela; Isabel Ray; Yixuan Ma; Ramesh Bhatt; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2163.

ARVO Annual Meeting Abstract June 2024

Interim results from the PRISM randomized phase 2 dose expansion trial evaluating 4D-150 in high anti-VEGF need individuals with neovascular (wet) age-related macular degeneration

Arshad M. Khanani; Allen Hu; David Aaron Eichenbaum; Raj K Maturi; Veeral S Sheth; Albert O Edwards; Sunil Gupta; Joel Pearlman; Suhail Alam; Jeffrey S Heier; Fuad Makkouk; Andres Emanuelli; Dante Pieramici; John A Wells; Chyong Nien; Robert Kim

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4356.

ARVO Annual Meeting Abstract June 2024

The EC50 binding characteristics of novel trispecific protein, RO-104

Parth Patel; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Alina K Sinha; Nikhil Gupta; Ashwin Gupta; Megana Paidela; Isabel Ray; Yixuan Ma; Jessi Prentice; Ramanath Bhandari; Ramesh Bhatt

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5088.

ARVO Annual Meeting Abstract June 2024

Binding characteristics of a novel trispecific protein RO-104 to aflibercept

Megana Paidela; Li Xu; Peter M Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Parth Patel; Nikhil Gupta; Ashwin Gupta; Alina K Sinha; Isabel Ray; Yixuan Ma; Ramesh Bhatt; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1950.

ARVO Annual Meeting Abstract June 2024

Characterization of the Receptor-Ligand Competition of RO-104 IC50 Potencies

Ashwin Gupta; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Ramesh Bhatt; Parth Patel; Alina K Sinha; Nikhil Gupta; Megana Paidela; Isabel Ray; Yixuan Ma; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):264.

ARVO Annual Meeting Abstract June 2024

Pharmacokinetic Analysis of RO-104 in Rabbit Eye Vitreous

Nikhil Gupta; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Parth Patel; Ashwin Gupta; Alina K Sinha; Megana Paidela; Isabel Ray; Yixuan Ma; Ramesh Bhatt; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):263.

ARVO Annual Meeting Abstract June 2024

Long-term efficacy and safety of pegcetacoplan over 36 months including 12-month results of the GALE open-label extension study

Ashkan Michael Abbey; Charles C Wykoff; Jeffrey S Heier; Chao Li; Felix Yemanyi; Gabriela Dieckmann; Daniel Pereria; Min Tsuboi; Caroline Baumal

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):380.

ARVO Annual Meeting Abstract June 2024

Aflibercept 8 mg monotherapy shows maintained efficacy over 96 weeks, with the ability to extend dosing intervals beyond every 16 weeks, in patients with PCV in the PULSAR Phase 3 trial

Rufino Silva; Tien Y Wong; Gemmy Cheung; Jeffrey S Heier; Won Ki Lee; Tomohiro Iida; xin Zhang; Tobias Machewitz; Andrea Schulze; Sergio Leal

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):219.

ARVO Annual Meeting Abstract June 2024

The 18-Month Efficacy of Avacincaptad Pegol in Geographic Atrophy: Pooled Results from GATHER1 and GATHER2

Greggory Gahn; Peter K Kaiser; Arshad M. Khanani; Carl J Danzig; Jeffrey S Heier; Julie Clark; Liansheng Zhu; Hersh Patel; Don Luo; Nikhil Patel; Glenn J Jaffe

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4400.

ARVO Annual Meeting Abstract June 2023

Pooled safety analysis of a single intravitreal injection of JNJ-1887 (gene therapy, AAVCAGsCD59) in patients with age-related macular degeneration (AMD)

Eleonora M Lad; Daniel L Chao; Anthony Pepio; Wei Zhang; George Capuano; Adam Rogers; Brad J Baker; Michael Cohen; H. Nida Sen; Jeffrey S Heier

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):732.

ARVO Annual Meeting Abstract June 2023

Intravitreal aflibercept 8 mg in patients with polypoidal choroidal vasculopathy (PCV): A Phase 3 PULSAR trial subgroup analysis

Tien Y Wong; Jeffrey S Heier; Xin Zhang; Tobias Machewitz; Andrea Schulze; Sergio Leal

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2240.

ARVO Annual Meeting Abstract June 2023

Treatment response to avacincaptad pegol by baseline patient characteristics: A prespecified subgroup analysis of the phase 3 GATHER2 study

Carl J Danzig; Peter Kaiser; David Lally; Glenn J Jaffe; Arshad M. Khanani; Charles Clifton Wykoff; Jeffrey S Heier; Justin Tang; Liansheng Zhu; Julie Clark

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):984.

ARVO Annual Meeting Abstract June 2023

The Characterization of the Ang-2 Arm of a Novel Anti-VEGF-A and Ang-2 Bispecific Protein (RO-101) in Comparison to Faricimab-svoa

Megana Paidela; Li Xu; Parth Patel; John Mitchell Kunzeman; Jessi Prentice; Robert Lowenthal; Mark Barakat; Arshad M. Khanani; Peter K Kaiser; Jeffrey L. Olson; Jeffrey S Heier; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):739.

ARVO Annual Meeting Abstract June 2023

Binding Characteristics of the VEGF Arm of a Novel Bispecific Protein RO-101 in Comparison to Faricimab-svoa

Parth Patel; Li Xu; Megana Paidela; John Mitchell Kunzeman; Jessi Prentice; Mark Barakat; Robert Lowenthal; Arshad M. Khanani; Peter M Kaiser; Jeffrey S Heier; Jeffrey L. Olson; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):738.

Retina June 2022

The Association of Fluid Volatility With Subretinal Hyperreflective Material and Ellipsoid Zone Integrity in Neovascular AMD

PDF

Justis P. Ehlers; Nikhil Patel; Peter K. Kaiser; Jeffrey S. Heier; David M. Brown; Xiangyi Meng; Jamie Reese; Leina Lunasco; Thuy K. Le; Ming Hu; Sunil K. Srivastava
TAGS: exudative age-related macular degeneration, eye, personal integrity, volume, attenuation
Invest. Ophthalmol. Vis. Sci.. 2022; 63(6):17. https://doi.org/10.1167/iovs.63.6.17

Includes: Supplemental Content

1 2 3

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Safety, Tolerability and Efficacy of Intravitreal AM712 for Neovascular Age-Related Macular Degeneration (CONQUER)

RO-104, a trispecific antibody, significantly reduces vascular leakage and lesion area in laser-induced non-human primate model of CNV

RP-060: a potential bispecific molecule targeting both dry AMD and wet AMD pathways

Inhibition of VEGFA induced HUVEC migration via RO-104, a novel trispecific protein

Assessment of pre-existing anti-drug antibodies (ADAs) in pooled serum against novel trispecific biologic RO-104 analogs

Rat Laser CNV Efficacy Studies with the Novel Trispecific Protein RO-104

Interim results from the PRISM randomized phase 2 dose expansion trial evaluating 4D-150 in high anti-VEGF need individuals with neovascular (wet) age-related macular degeneration

The EC50 binding characteristics of novel trispecific protein, RO-104

Binding characteristics of a novel trispecific protein RO-104 to aflibercept

Characterization of the Receptor-Ligand Competition of RO-104 IC50 Potencies

Pharmacokinetic Analysis of RO-104 in Rabbit Eye Vitreous

Long-term efficacy and safety of pegcetacoplan over 36 months including 12-month results of the GALE open-label extension study

Aflibercept 8 mg monotherapy shows maintained efficacy over 96 weeks, with the ability to extend dosing intervals beyond every 16 weeks, in patients with PCV in the PULSAR Phase 3 trial

The 18-Month Efficacy of Avacincaptad Pegol in Geographic Atrophy: Pooled Results from GATHER1 and GATHER2

Pooled safety analysis of a single intravitreal injection of JNJ-1887 (gene therapy, AAVCAGsCD59) in patients with age-related macular degeneration (AMD)

Intravitreal aflibercept 8 mg in patients with polypoidal choroidal vasculopathy (PCV): A Phase 3 PULSAR trial subgroup analysis

Treatment response to avacincaptad pegol by baseline patient characteristics: A prespecified subgroup analysis of the phase 3 GATHER2 study

The Characterization of the Ang-2 Arm of a Novel Anti-VEGF-A and Ang-2 Bispecific Protein (RO-101) in Comparison to Faricimab-svoa

Binding Characteristics of the VEGF Arm of a Novel Bispecific Protein RO-101 in Comparison to Faricimab-svoa

The Association of Fluid Volatility With Subretinal Hyperreflective Material and Ellipsoid Zone Integrity in Neovascular AMD

To View More...

You must be signed into an individual account to use this feature.